Join the DDA or

Accord irbesartan recall

Contamination risk

February 15th 2019

Tagged: MHRA alert

By Ailsa Colquhoun

Actavis Group PTC EHF is recalling the following batches of irbesartan as a precautionary measure due to possible contamination with the carcinogen N‑nitrosodiethylamine (NDEA).

Irbesartan 300mg film-coated tablets, PL 30306/0108

Batch number Expiry date Pack size First distributed
191018 05/2020 1 x 28 30 Nov 2018
191118 05/2020 1 x 28 20 Dec 2018

Irbesartan/hydrochlorothiazide 300/25mg film-coated tablets, PL 30306/0267

Batch number Expiry date Pack size First distributed
263918 06/2020 1 x 28 21 Nov 2018

Healthcare professionals are asked to quarantine all remaining stock and return it to your supplier using your supplier’s approved process.

Patients should be advised to continue taking their medication as the health risk of discontinuing the medicine is higher than the potential risk presented by the contaminant. A treatment review is not necessary until the next routine appointment.

For more information:
Accord customer services: 0800 373573
Accord medical information: 01271 385257

For all the latest news of the 2019 DDA annual conference...

Learn more